Sales rep says he promoted Risperdal for off-label use
A sales representative for Janssen Pharmaceutica testified that he pushed doctors to consider prescribing antipsychotic drug Risperdal for unapproved use in "augmentation therapy." Matthew D. Thompson said in court that the company did not "think about augmentation in the realm of on-label or off-label at that time."
Bloomberg | 10/28
This story published in FMI Pharmacy dailyLead on 10/29/2009
More from SmartBrief:
J&J unit, Danish biotech firm sign drug-development deal
Tuesday, August 18, 2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|